Adropin dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Adropin is a peptide whose blood level is lower in people who are heavier and older. Every human study just measures it. No one has given adropin to a person, and the memory benefit that gets quoted was in ageing mice.
Evidence grade for Adropin: Preliminary. The rule: studied in people, but no published study has had people take it. The sum on this page: 1 human study where nobody was given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 0
- Found nothing
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
1 human study where nobody was given it
No first-hand reports gathered yet. That is a gap in what we have collected, not a finding that nothing has been reported.
Goal pages: Brain, memory and mood
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Adropin is a small peptide your body makes. Its blood level is lower in people who are heavier and older. It is linked to healthy metabolism in mice. Nobody has given it to a person.
What people take it for
- Better blood sugar control.
- Better memory, based on a mouse study.
What studies in people showed
Every human study only measures it. In 130 people, adropin was lower with more weight and older age. In 19 women who had weight loss surgery, it rose after the operation. That suggests weight loss raises adropin, not the other way round. The memory benefit was in ageing mice. No person has been treated with it.
What people report
Reports, not study results
The good
- We have not collected user reports on this one. It is not widely sold.
The bad
- No person has taken it in a study, so nobody knows its side effects.
Where these come from: Both lines are from the studies and notes on this page. We have not collected user reports on this one.
My bottom line
Low adropin looks like a sign of the problem, not the cause. Lose the fat and it goes up on its own. Work on the weight, not the marker.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Animal and lab work, not yet tested in people
Real results, but from animals or cells, not people. What works in a mouse often does not work the same way in a person. Nobody can patent this, so nobody would ever earn back the cost of a study in people. That is usually why there is none. The record on this one is set out below.
- Memory and thinking1 animal or lab study
35 of the 36 indexed goals have no study of any kind behind Adropin
No study in people, animals or cells on this page reports a result for these. That does not prove Adropin does nothing for them. It does mean anything you have heard about Adropin and one of these did not come from a study cited here.
Show full evidence
What is Adropin?
Adropin is a peptide whose blood level is lower in people who are heavier and older. Every human study just measures it. No one has given adropin to a person, and the memory benefit that gets quoted was in ageing mice.
Adropin is made from the ENHO gene and floats in the blood at very low levels. It came out of mouse work suggesting a peptide needed for healthy metabolism and for stopping the insulin resistance that comes with obesity.
The human studies that followed only measure it. In a 2012 study of 130 people, adropin was lower in people with a higher body mass index and in older people. It was higher in men than women. It was lower in overweight and obese people, though that weight link showed up only in men. Having two or more risk factors for metabolic syndrome went with lower adropin in both sexes. In 19 women followed through gastric bypass surgery, adropin rose after surgery and peaked at three months.
The most quoted paper has its own split in the title. A 2021 study reported that adropin tracks with age-related brain damage in people and improves thinking in ageing mice. The human half is a link with brain damage seen after death or on scans. The mouse half is the treatment. Shop copy merges the two into a claim that adropin improves thinking, which no human study has tested.
The trial registry lists adropin studies that only measure it: in gum disease, endometriosis cysts, how severe chronic diseases are, and a placenta problem called placenta accreta. In all of them adropin is something measured. Not one gives adropin to anybody.
How does Adropin work?
In animal work, adropin changes which fuel muscle burns, favouring sugar over fat. It also improves insulin sensitivity and the function of the blood vessel lining. Its receptor is not settled. GPR19 has been proposed and is disputed. A 2025 review calls adropin a heart and metabolism hormone in the body and a brain hormone in the brain. That is a way of saying the mechanism differs by tissue and is not pinned down in either.
What have studies in people found about Adropin?
There is a fair amount of human data, and all of it only measures adropin. It has never been given to a person in a registered study.
- 130 people: adropin falls as body mass index and age rise, is higher in men, and is lower in people with two or more metabolic syndrome risk factors.
- 19 women having gastric bypass: adropin rose after surgery and peaked at 3 months. That is a response to weight loss, not an effect of adropin as a treatment.
- A 2021 study reports a link between adropin and age-related brain damage in people. The better thinking in that paper was in mice.
- Registered human studies of adropin, including work in gum disease, endometriosis cysts and placenta accreta, all measure it as a marker.
What this does not tell you: A marker that falls with obesity and age tells you the company it keeps, not that it causes anything. Low adropin in metabolic disease fits just as well with adropin being a result of the disease. The gastric bypass data suggest exactly that: fix the obesity and adropin rises. Lab tests for blood peptides this size are a known problem in this field, and that has not been settled for adropin. Nothing here tells you what giving adropin to a person would do.
The state of the research
Adropin belongs with irisin and GDF-15: exercise and metabolism peptides where the whole human record is links and the whole treatment record is rodents. That pattern is worth naming, because the marketing does the opposite. It takes the mouse treatment and the human link and presents them as one body of evidence about people.
There is also no product. Unlike compounds that reach the research chemical market, adropin is not widely sold. This page exists mainly to stop the mouse memory result being quoted as a human one.
The most useful thing in the human data is the direction of the gastric bypass finding. Adropin rose after weight loss surgery. If adropin were driving metabolic health, you would expect the story to run the other way round. It is the same shape as the osteocalcin problem on the neighbouring page: the peptide tracks the state of the body rather than clearly setting it.
The evidence, in charts
Fig. 1a · how many people
85people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| The Journal of Clinical Endocrinology and Metabolism 2012 | 85 | 100% |
The whole total is one study of 85. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
1 of 3 sources here is a study in people. The rest are not.
- Study in people · done in people133%
- Animal study · done in animals133%
- Review of studies · sums up other studies133%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 3 different years, 2012 to 2025, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- Roughly 4.5 kDa for the secreted 43 residue form
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Not established in humans. No one has administered it, so there is no human pharmacokinetic study to draw on.
No amino acid sequence is on file for Adropin, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2012Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans
Adropin runs lower in people who are heavier and older, and nobody was given any. 130 people had their blood measured. Levels fell as weight and age rose, and men carried more of it than women. The drop with extra weight showed up only in men. In 19 women who had gastric bypass surgery, levels rose and peaked three months after the operation. This is watching what was already there. It does not show that raising adropin would do anything.
85 women and 45 men. Adropin correlated negatively with BMI (r = -0.335, p < 0.001) and age (r = -0.263, p = 0.003), was higher in men (4.1 ng/mL) than women (3.0 ng/mL, p = 0.001), and was lower in overweight (3.3 ng/mL) and obese (2.7 ng/mL) than healthy-weight participants (4.1 ng/mL), with the weight effect confined to men. In 19 women having gastric bypass, adropin rose and peaked 3 months after surgery. Observational throughout.
- Review of studies2025Adropin: A cardio-metabolic hormone in the periphery, a neurohormone in the brain?
A 2025 review of adropin. The question mark in its title is the authors' own. It shows how unsettled its receptor and its actions in different tissues still are.
Recent review of the field. The question mark in the title is the authors', and it reflects how unsettled the receptor biology and the tissue-specific actions remain.
- Animal study2021Adropin correlates with aging-related neuropathology in humans and improves cognitive function in aging mice
Two findings in one paper. In people, adropin levels tracked with age-related brain damage, which is just a link. The treatment, and the better thinking, was in ageing mice.
Read the title as two studies. The human component is a correlation between adropin and ageing-related neuropathology. The intervention, and the cognitive improvement, is in aging mice. Classified here as animal because that is where the treatment was given.
Where to buy Adropin
No seller we track lists Adropin yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has Adropin been tested in people?
Not in a completed trial cited here. 1 human study where nobody was given it. Adropin is a peptide whose blood level is lower in people who are heavier and older. Every human study just measures it. No one has given adropin to a person, and the memory benefit that gets quoted was in ageing mice.
What is the Adropin dosage?
No human dose established. No published study on this page has given this compound to people and reported a result. 1 human study where nobody was given it
Is Adropin FDA-approved?
Not a drug. Adropin is a peptide the body makes, measured in research studies. No adropin product is approved anywhere, and no trial giving it to people has been registered.
Can I buy adropin?
It is not sold as an established product and has never been given to a person in a registered study. Anything sold under that name has no human data at all on how the body handles it or whether it is safe.
Does adropin improve memory?
In ageing mice, yes, in the study that reported it. The human part of that same paper is a link between adropin levels and age-related brain damage. No person has been treated with adropin for memory or anything else.
Does exercise raise adropin?
Adropin is lower with obesity and age and rises after weight loss surgery, so it moves with the body's metabolic state. Exercise studies that measure it exist, but they are small and do not agree, and none shows that changing adropin changes a health outcome.
Is a low adropin level something to treat?
There is nothing to treat it with, and no evidence that raising it would help. Low adropin goes with a high body mass index, older age and metabolic syndrome risk factors. All of those have treatments of their own with real outcome data.